Therefore, an examination of the regulatory effects of BMAL1 on the expression of the angiogenic factors ANG1 (Angiopoietin 1), ANG2, and VEGF in glioma will be conducive to understanding the reasons for glioma tolerance to vascular targeted therapy and the development of new target drugs. The gene discussed is VEGFA; the disease is central nervous system cancer.